



Trento, March 29, 2010

TwoF Inc., a company based in California with a controlling stake in Molecular Stamping S.r.l., announced early today a capital increase of US \$2 million with a pool of new international investors, including two companies from Trentino Alto Adige: La Finanziaria Trentina S.p.A. and Enthofin S.r.l.; new investors are joining Innogest Capital, the leading Venture Capital fund in Italy and other existing investors.

Based in Trento within the *Fondazione Bruno Kessler*, Molecular Stamping is a highly innovative company focused on the development and commercialization of genetic analysis assays produced thanks to its proprietary technology “Supramolecular Nanostamping”.

The company is an outstanding example of scientific and technological research in the Trentino Alto Adige region. Founded in 2006, the firm’s focus is the development and the commercialization of the research conducted by Prof. Francesco Stellacci on nanotechnologies and material sciences at MIT (Massachusetts Institute of Technology). Molecular Stamping has achieved several important milestones to-date: it has submitted 7 international patent applications and it is currently in the process of filing 4 additional patents. Furthermore, it has set up a unique production plant to manufacture industrial quantities of microarrays. The company currently employs 14 highly skilled resources – amongst which several holding a PhD in biology or chemistry – led by Giovanni De Ceglia, a manager with extensive experience with global technology leading companies such as Texas Instruments, Cisco and Pirelli.

Thanks to its innovative approach in DNA microarray manufacturing, Molecular Stamping is developing products that aim at the identification of genetic mutations, useful in fields such as oncology and in-vitro fertilisation.

The initial R&D phase has been a success, and has attained important technological and industrial results. The current capital increase is intended to finance the further development and technology improvement phase which will allow the company to market the first DNA Microarray “Made in Trento” during the course of next year.

Amongst the company’s accessible markets, genetic analysis in oncology is growing rapidly, with a potential estimate of 600,000 analysis per year for the top genetic oncology.

La Finanziaria Trentina is a company owned by approximately 40 entrepreneurs from the Trentino Alto Adige region. Every year it allocates a portion of its funds in venture capital investments which has significant and positive impact on the employment of the region.

Innogest Capital has €80 million under management for seed and early stage investments in young, ambitious and high growth potential entrepreneurial companies.